FectoVIR®-AAV GMP
FectoVIR®-AAV is a novel generation of synthetic transfection reagent specifically developed for industrial scale production of recombinant AAV (rAAV) in both suspension and adherent HEK-293 derivative cell systems
- Item No.:
- 102000006
*Custom/bulk order quotes are provided within 72 hours of request.
FectoVIR®-AAV transfection reagent guarantees higher rAAV titers, improves scalability for large scale production and de-risks manufacturing process with its availability at pharma GMP grade. FectoVIR®-AAV-GMP is manufactured under a validated and aseptic process in compliance with ICH Q7, GMP part II guidelines, the quality grade of reference for active pharmaceutical ingredients (API).
Key Benefits:
- Process Economics: High AAV productivity expands the number of doses per batch to reduce manufacturing costs.
- Industrial Scalability: Designed for large scale with low complexation volume, long complex stability, and high reproducibility.
- GMP Grade Availability: Validated Manufacturing process following ICH Q7 guidelines, provided with full regulatory documentation.
- Risks Mitigation: Both residual test and toxicity statement enable to mitigate risks and ensure patient safety.
Datasheet
Other
Poster
Technical Note
Applications
-
ApplicationrAAV (Adeno-Associated Virus) manufacturing using HEK-293 derivative cells
Biological Information
-
Number of transfections1 L of FectoVIR®-AAV transfection reagent is sufficient to transfect on average 500 L of cell culture (using standard conditions)
Compliance Information
-
GMP ComplianceYes
-
OriginAnimal-Component Free
-
Product Documentation
-
Protocol
-
Certificate of Analysis
-
Certificate of origin
-
Non-hazardous product statement
-
Certificate of compliance
-
Drug master file
-
Protocols for identity and activity testing
-
Regulatory support package including toxicity statement
- Quality agreement
-
Protocol
General Specifications
-
Amount of ReagentFectoVIR®-AAV GMP 100 mL Bottle
Storage Conditions
-
Storage Conditions5 °C ± 3 °C